Alnylam touts label expansion for rare oxalate disease
Almost two years after securing its third drug approval, Alnylam is touting an expanded label for Oxlumo.
The company put out word on Thursday night that the FDA approved an sNDA for its treatment lumasiran for primary hyperoxaluria type 1, also known as Ph1. The rare genetic disease, in which the body is unable to regulate the overproduction of oxalate, can spur the development of kidney stones and play a role in later-stage kidney disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.